Researchers find a promising new approach for treating liver cirrhosis

Increased pressure in the veins leading to the liver, known as portal hypertension (PH), accounts for the majority of medical complications and deaths associated with cirrhosis.

Therefore, a tremendous need exists to find drugs that simultaneously treat the multiple pathologies associated with chronic PH. In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH. This suggests a promising new approach for treating liver cirrhosis.

To read the full story, visit: medicalexpress.com